Are	VBP
mast	NN
cells	NNS
instrumental	JJ
for	IN
fibrotic	JJ
diseases	NNS
?	.

Idiopathic	JJ
pulmonary	JJ
fibrosis	NN
(	(
IPF	NN
)	)
is	VBZ
a	DT
fatal	JJ
lung	NN
disorder	NN
of	IN
unknown	JJ
etiology	NN
characterized	VBN
by	IN
accumulation	NN
of	IN
lung	NN
fibroblasts	NNS
and	CC
extracellular	JJ
matrix	NN
deposition	NN
,	,
ultimately	RB
leading	VBG
to	TO
compromised	VBN
tissue	NN
architecture	NN
and	CC
lung	NN
function	NN
capacity	NN
.	.

IPF	NN
has	VBZ
a	DT
heterogeneous	JJ
clinical	JJ
course	NN
;	:
however	RB
the	DT
median	JJ
survival	NN
after	IN
diagnosis	NN
is	VBZ
only	RB
3-5	CD
years	NNS
.	.

The	DT
pharmaceutical	JJ
and	CC
biotechnology	NN
industry	NN
has	VBZ
made	VBN
many	JJ
attempts	NNS
to	TO
find	VB
effective	JJ
treatments	NNS
for	IN
IPF	NN
,	,
but	CC
the	DT
disease	NN
has	VBZ
so	RB
far	RB
defied	VBN
all	DT
attempts	NNS
at	IN
therapeutic	JJ
intervention	NN
.	.

Clinical	JJ
trial	NN
failures	NNS
may	MD
arise	VB
for	IN
many	JJ
reasons	NNS
,	,
including	VBG
disease	NN
heterogeneity	NN
,	,
lack	NN
of	IN
readily	RB
measurable	JJ
clinical	JJ
end	NN
points	NNS
other	JJ
than	IN
overall	JJ
survival	NN
,	,
and	CC
,	,
perhaps	RB
most	JJS
of	IN
all	DT
,	,
a	DT
lack	NN
of	IN
understanding	NN
of	IN
the	DT
underlying	VBG
molecular	JJ
mechanisms	NNS
of	IN
the	DT
progression	NN
of	IN
IPF	NN
.	.

The	DT
precise	JJ
link	NN
between	IN
inflammation	NN
and	CC
fibrosis	NN
remains	VBZ
unclear	JJ
,	,
but	CC
it	PRP
appears	VBZ
that	IN
immune	JJ
cells	NNS
can	MD
promote	VB
fibrosis	NN
by	IN
releasing	VBG
fibrogenic	JJ
factors	NNS
.	.

So	RB
far	RB
,	,
however	RB
,	,
therapeutic	JJ
approaches	NNS
targeting	VBG
macrophages	NNS
,	,
neutrophils	NNS
,	,
or	CC
lymphocytes	NNS
have	VBP
failed	VBN
to	TO
alter	VB
disease	NN
pathogenesis	NN
.	.

A	DT
new	JJ
cell	NN
to	TO
garner	VB
research	NN
interest	NN
in	IN
fibrosis	NN
is	VBZ
the	DT
mast	NN
cell	NN
.	.

Increased	VBN
numbers	NNS
of	IN
mast	NN
cells	NNS
have	VBP
long	RB
been	VBN
known	VBN
to	TO
be	VB
present	JJ
in	IN
pulmonary	JJ
fibrosis	NN
and	CC
clinically	RB
correlations	NNS
between	IN
mast	NN
cells	NNS
and	CC
fibrosis	NN
have	VBP
been	VBN
reported	VBN
.	.

More	RBR
recent	JJ
data	NNS
suggests	VBZ
that	IN
mast	NN
cells	NNS
may	MD
contribute	VB
to	TO
the	DT
fibrotic	JJ
process	NN
by	IN
stimulating	VBG
fibroblasts	NNS
resident	JJ
in	IN
the	DT
lung	NN
,	,
thus	RB
driving	VBG
the	DT
pathogenesis	NN
of	IN
the	DT
disease	NN
.	.

In	IN
this	DT
review	NN
,	,
we	PRP
will	MD
discuss	VB
the	DT
mast	NN
cell	NN
and	CC
its	PRP$
physiological	JJ
role	NN
in	IN
tissue	NN
repair	NN
and	CC
remodeling	NN
,	,
as	RB
well	RB
as	IN
its	PRP$
pathological	JJ
role	NN
in	IN
fibrotic	JJ
diseases	NNS
such	JJ
as	IN
IPF	NN
,	,
where	WRB
the	DT
process	NN
of	IN
tissue	NN
repair	NN
and	CC
remodeling	NN
is	VBZ
thought	VBN
to	TO
be	VB
dysregulated	VBN
.	.

